Despite the limited studies on ALYREF in tumors, Zhao, Zheng et al. reported that ALYREF may serve as a marker for assessing tumorigenesis and therapeutic efficacy [14], and could be incorporated into prognostic models for ovarian cancer [15]. This evidence concerns the gene ALYREF and ovarian carcinoma.